Collplant Holdings (CLGN) AI Stock Analysis

157 Followers

Top Page

Collplant Holdings

(NASDAQ:CLGN)

38Underperform

Collplant Holdings is currently experiencing significant financial difficulties, with sharp declines in revenue and cash flow, and substantial net losses. The technical indicators suggest ongoing negative momentum, and the valuation is unattractive due to persistent losses. While the earnings call offered some optimism with promising product developments and a solid cash runway, these are overshadowed by the financial challenges. The overall score reflects these concerns, indicating a high-risk investment.

Positive Factors

Partnerships

CollPlant continues to progress the clinical development of its dermal and soft-tissue filler program in collaboration with AbbVie.

Product Development

Encouraging initial breast implant data shows signs of implant integration and rapid growth of native tissue, supporting potential future commercialization.

Negative Factors

Financial Performance

The company reported total revenues of $0.25M, compared to the consensus estimate of $0.69M.

Collplant Holdings (CLGN) vs. S&P 500 (SPY)

Market Cap

$28.18M

Dividend YieldN/A

Average Volume (3M)9.92K

Price to Earnings (P/E)―

Beta (1Y)0.54

Revenue Growth-95.30%

EPS Growth-135.89%

CountryUS

Employees57

SectorHealthcare

Sector Strength77

IndustryBiotechnology

Share Statistics

EPS (TTM)-1.45

Shares Outstanding11,454,512

10 Day Avg. Volume15,281

30 Day Avg. Volume9,921

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)3.24

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$11.00

Price Target Upside358.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering0

Collplant Holdings Business Overview & Revenue Model

Company DescriptionCollPlant Holdings (CLGN) is a regenerative and aesthetic medicine company specializing in the development and commercialization of innovative technologies and products for tissue regeneration and organ manufacturing. The company's core technology platform is based on recombinant human collagen (rhCollagen), which is produced using genetically engineered tobacco plants. CollPlant focuses on areas such as 3D bioprinting of tissues and organs, and dermal fillers for aesthetics, providing advanced solutions in the field of regenerative medicine.

How the Company Makes MoneyCollPlant Holdings generates revenue primarily through the sale and licensing of its proprietary rhCollagen-based products and technologies. The company's key revenue streams include direct product sales, licensing agreements, and collaborations with other biotechnology or pharmaceutical companies. Significant partnerships, such as those with 3D bioprinting firms and aesthetic medicine companies, contribute to its earnings by providing access to broader markets and co-development opportunities. Additionally, CollPlant might receive milestone payments and royalties from partners who utilize its technologies in their own product development.

Collplant Holdings Financial Statement Overview

Summary

Collplant Holdings is facing financial challenges, characterized by significant revenue and cash flow declines, negative profit margins, and shrinking assets and equity. Despite maintaining low debt levels, the company's ability to generate revenue and positive cash flow remains a concern. The biotechnology industry involves substantial R&D investment, which may explain some financial strain, but the current trajectory indicates potential risk without strategic improvements.

Income Statement

Negative

Collplant Holdings has experienced significant revenue volatility, with a notable revenue decline from $10.96 million in 2023 to $0.515 million in 2024. The company is struggling with negative margins, including a gross profit margin of -215% and a net profit margin of -3226% in 2024. Despite a brief profitable period in 2021, consistent negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

Neutral

The company's debt-to-equity ratio remains low at 0.23 in 2024, reflecting a conservative leverage approach. However, stockholders' equity has decreased significantly, and the equity ratio has dropped from 88% in 2021 to 72% in 2024, indicating weakening financial stability. The company's asset base has also shrunk considerably over the same period.

Cash Flow

Negative

Collplant Holdings' free cash flow has deteriorated significantly, with a negative free cash flow of $14.58 million in 2024, compared to $3.72 million in 2023. The operating cash flow to net income ratio and free cash flow to net income ratio are both negative, showing a lack of cash flow generation. Despite previous years of positive cash flow from financing activities, the company's cash reserves are depleting.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
515.00K	10.96M	299.00K	15.64M	6.14M
	Gross Profit
-1.11M	8.97M	-101.00K	13.64M	3.13M
	EBIT
-17.25M	-7.51M	-17.10M	65.00K	-5.60M
	EBITDA
-16.21M	-6.41M	-16.02M	838.00K	-4.94M
	Net Income Common Stockholders
-16.61M	-7.02M	-16.75M	409.00K	-5.81M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
11.91M	26.67M	29.65M	43.30M	3.33M
	Total Assets
18.71M	34.13M	37.77M	51.22M	10.84M
	Total Debt
3.08M	3.16M	2.91M	3.61M	3.39M
	Net Debt
-8.83M	-23.52M	-26.74M	-9.54M	55.00K
	Total Liabilities
5.25M	5.79M	5.49M	6.10M	6.36M
	Stockholders Equity
13.46M	28.34M	32.28M	45.12M	4.48M
Cash Flow		Free Cash Flow
-14.58M	-3.72M	-15.01M	912.00K	-4.97M
	Operating Cash Flow
-14.09M	-2.76M	-13.70M	2.50M	-4.45M
	Investing Cash Flow
-539.00K	-1.16M	28.92M	-31.56M	-519.00K
	Financing Cash Flow
9.00K	1.11M	1.87M	38.76M	4.46M

Collplant Holdings Technical Analysis

Technical Analysis Sentiment

Negative

Last Price2.40

Price Trends

50DMA

3.29

Negative

100DMA

3.64

Negative

200DMA

4.18

Negative

Market Momentum

MACD

-0.22

Positive

RSI

27.50

Positive

STOCH

4.18

Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Negative. The current price of 2.4 is below the 20-day moving average (MA) of 2.89, below the 50-day MA of 3.29, and below the 200-day MA of 4.18, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 27.50 is Positive, neither overbought nor oversold. The STOCH value of 4.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLGN.

Collplant Holdings Risk Analysis

Collplant Holdings disclosed 81 risk factors in its most recent earnings report. Collplant Holdings reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Collplant Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (48)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORGO	68 Neutral	$490.82M	694.64	0.26%	―	11.29%	-79.52%
MDXG	67 Neutral	$1.04B	24.92	25.01%	―	8.52%	-32.91%
RCEL	55 Neutral	$197.68M	―	-230.96%	―	32.24%	-66.93%
VERU	52 Neutral	$83.41M	―	-80.11%	―	-7.43%	69.03%
Sector *	48 Neutral	$6.35B	1.19	-46.87%	2.63%	17.16%	1.34%
CLGN	38 Underperform	$28.18M	―	-79.46%	―	-95.30%	-135.89%
NXTC	37 Underperform	$10.93M	―	-61.87%	―	―	11.66%

* Healthcare Sector Average

Performance Comparison

CLGN

Collplant Holdings

2.40

-2.82

-54.02%

VERU

Veru

0.57

-0.60

-51.28%

RCEL

Avita Medical

7.76

-7.21

-48.16%

MDXG

MiMedx Group

7.09

0.07

1.00%

ORGO

Organogenesis Holdings

3.89

0.97

33.22%

NXTC

NextCure

0.38

-1.51

-79.89%

Collplant Holdings Earnings Call Summary

Earnings Call Date: Mar 26, 2025 | % Change Since: -14.29% | Next Earnings Date: May 22, 2025

Earnings Call Sentiment Neutral

Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.

Highlights

Photocurable Dermal Filler Preclinical Success

The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a compound annual growth rate of 10%. Positive feedback from leaders in aesthetic medicine suggests it could be a game-changer for facial plastic surgery.

Regenerative Breast Implant Program Progress

Preclinical testing of commercial-sized breast implants (250cc) shows promising outcomes with depolarization and rapid tissue ingrowth, no complications, and maintained volume retention. This product could revolutionize breast reconstruction and aesthetic enhancements.

AbbVie Collaboration and Financial Milestone

CollPlant received a $2 million payment from AbbVie following development achievements in their dermal filler clinical trials, indicative of continued collaboration and potential future milestones.

Cash Runway Stability

Cash and cash equivalents as of December 31, 2024, were $11.9 million, with an expected operational runway through the second quarter of 2026.

Lowlights

Significant Revenue Decline

Revenue for the year ended December 31, 2024, was $515,000, a sharp decrease from $11 million in 2023, mainly due to a $10 million milestone payment in 2023 not repeated in 2024.

Increased Net Loss

GAAP net loss for the year ended December 31, 2024, was $16.6 million compared to a net loss of $7 million for the year 2023, highlighting increased financial strain.

Company Guidance

During the CollPlant Biotechnologies Ltd. investor call, CEO Yehiel Tal and Deputy CEO Eran Rotem provided guidance centered on their regenerative medicine advancements, notably highlighting their proprietary photocurable dermal filler and regenerative breast implant programs. The dermal filler, aimed at a market valued at approximately $6.3 billion with a 10% CAGR, is currently in the preclinical phase, with plans to launch a clinical trial within two years. The regenerative breast implant program is progressing with preclinical testing of 250cc commercial-sized prototypes, showing promising results in tissue integration without complications. Financially, CollPlant reported a decrease in revenue from $11 million in 2023 to $515,000 in 2024, primarily due to a $10 million milestone payment from AbbVie in 2023. Despite a GAAP net loss of $16.6 million in 2024 compared to $7 million in 2023, the company maintains a stable cash position of $11.9 million as of December 31, 2024, not accounting for an additional $2 million payment from AbbVie, ensuring operational capability into the second quarter of 2026.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.